AU780892B2 - Improved cancer treatment with temozolomide - Google Patents

Improved cancer treatment with temozolomide Download PDF

Info

Publication number
AU780892B2
AU780892B2 AU39244/00A AU3924400A AU780892B2 AU 780892 B2 AU780892 B2 AU 780892B2 AU 39244/00 A AU39244/00 A AU 39244/00A AU 3924400 A AU3924400 A AU 3924400A AU 780892 B2 AU780892 B2 AU 780892B2
Authority
AU
Australia
Prior art keywords
temozolomide
day
period
daily dose
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39244/00A
Other languages
English (en)
Other versions
AU3924400A (en
Inventor
Mohamed H. Ragab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU3924400A publication Critical patent/AU3924400A/en
Application granted granted Critical
Publication of AU780892B2 publication Critical patent/AU780892B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: SCHERING CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU39244/00A 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide Ceased AU780892B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134899A 1999-03-30 1999-03-30
US09/281348 1999-03-30
PCT/US2000/008079 WO2000057867A2 (en) 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide

Publications (2)

Publication Number Publication Date
AU3924400A AU3924400A (en) 2000-10-16
AU780892B2 true AU780892B2 (en) 2005-04-21

Family

ID=23076905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39244/00A Ceased AU780892B2 (en) 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide

Country Status (18)

Country Link
EP (1) EP1165071B1 (https=)
JP (2) JP2002540148A (https=)
CN (2) CN1345240A (https=)
AR (1) AR023185A1 (https=)
AT (1) ATE310515T1 (https=)
AU (1) AU780892B2 (https=)
BR (1) BR0009380A (https=)
CA (1) CA2368614C (https=)
DE (1) DE60024243T2 (https=)
DK (1) DK1165071T3 (https=)
ES (1) ES2251987T3 (https=)
HK (1) HK1044111B (https=)
HU (1) HUP0200805A3 (https=)
NO (1) NO330651B1 (https=)
NZ (1) NZ536302A (https=)
TW (1) TWI276434B (https=)
WO (1) WO2000057867A2 (https=)
ZA (1) ZA200107736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
CN1299772C (zh) * 2004-10-14 2007-02-14 孔庆忠 一种抗癌药物组合物
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
SG10201500028RA (en) * 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
JP5199263B2 (ja) * 2006-09-29 2013-05-15 シプラ・リミテッド テモゾロミドと類似体を調製するための改善された方法
US20140005160A1 (en) * 2010-12-01 2014-01-02 Hooshmand SHESHBARADARAN Method for Treating Refractory Cancer
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN107397735B (zh) * 2017-07-28 2020-07-10 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) * 2023-11-24 2024-01-05 郑州德迈药业有限公司 一种替莫唑胺制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
CA2184546A1 (en) * 1996-07-31 1998-02-01 Margaret H. Dugan Method for treating pediatric high grade astrocytoma including brain stem glioma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2233544A1 (en) * 1995-10-04 1997-04-10 Schering Corporation Combination temozolomide and alpha-ifn for the treatment of advanced cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
CA2184546A1 (en) * 1996-07-31 1998-02-01 Margaret H. Dugan Method for treating pediatric high grade astrocytoma including brain stem glioma

Also Published As

Publication number Publication date
HK1044111A1 (en) 2002-10-11
AR023185A1 (es) 2002-09-04
CN1345240A (zh) 2002-04-17
DE60024243D1 (de) 2005-12-29
BR0009380A (pt) 2001-12-26
NO20014725L (no) 2001-11-13
HUP0200805A2 (hu) 2002-07-29
DE60024243T2 (de) 2006-08-17
CA2368614C (en) 2008-07-22
NO20014725D0 (no) 2001-09-28
ES2251987T3 (es) 2006-05-16
NO330651B1 (no) 2011-05-30
HK1044111B (en) 2006-02-24
ATE310515T1 (de) 2005-12-15
WO2000057867A2 (en) 2000-10-05
AU3924400A (en) 2000-10-16
NZ536302A (en) 2006-05-26
ZA200107736B (en) 2003-02-26
EP1165071B1 (en) 2005-11-23
WO2000057867A3 (en) 2001-04-19
JP2002540148A (ja) 2002-11-26
EP1165071A2 (en) 2002-01-02
JP2007169297A (ja) 2007-07-05
TWI276434B (en) 2007-03-21
CA2368614A1 (en) 2000-10-05
DK1165071T3 (da) 2006-02-20
CN102160864A (zh) 2011-08-24
HUP0200805A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
US5939098A (en) Cancer treatment with temozolomide
JP2007169297A (ja) テモゾロミドを用いる改善された癌処置
US7910580B2 (en) Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer
US6346524B1 (en) Cancer treatment with temozolomide
US7705049B2 (en) Methods for treating non-melanoma cancers with PABA
TW202333675A (zh) 用於治療癌症之組合療法之用途
US5824346A (en) Combination therapy for advanced cancer
CA2184545A1 (en) Cancer treatment with temozolomide
CA2435921C (en) Method of cancer therapy
EP1208840B1 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
Tankanow Docetaxel: a taxoid for the treatment of metastatic breast cancer
JP2003521497A (ja) 癌のための組み合せ治療
EP0858341B1 (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
DeMario et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
MXPA01009926A (en) Improved cancer treatment with temozolomide
Zalupski et al. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma
US5942247A (en) Method for treating pediatric high grade astrocytoma including brain stem glioma
CN102014895A (zh) 组合抗癌剂
RU2341260C2 (ru) Комбинации, включающие производные эпотилона и алкилирующие агенты
US4005203A (en) Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine
CA2184546A1 (en) Method for treating pediatric high grade astrocytoma including brain stem glioma
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent